FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W74851999> ?p ?o ?g. }

• W74851999 abstract "Angiogenesis is an important mediator in tumor progression. Vascular endothelial growth factor (VEGF) is one of the major cytokines that can influence angiogenesis. However, the potential mechanism of tumor growth inhibition through anti-VEGF agents is still unclear. This study was performed to examine whether ranibizumab could inhibit malignant melanoma growth in vitro and to determine the safety of ranibizumab on human adult retinal pigment epithelium cell line (ARPE-19 cells).Malignant melanoma cells obtained from a clinic were cultured in vitro. VEGF concentrations secreted by malignant melanoma cells and the ARPE-19 cells were examined by enzyme-linked immunosorbent assay (ELISA). The two kinds of cells were both treated with VEGF and its antagonist, ranibizumab. The dynamic changes of the two types of cells were monitored by real-time cell electronic sensing (RT-CES) assay. The effect of ranibizumab on both types of cells was verified by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl (MTT) assay. The expression of VEGF receptor 1 (VEGFR1) RNA in uveal melanoma was further investigated through the PCR technique.The levels of VEGF secreted by malignant melanoma cells were much higher than those of ARPE-19 cells, and were markedly decreased in the action of 0.1 mg/ml ranibizumab. However, there was no obvious reduction of VEGF in the presence of ranibizumab for ARPE-19 (p>0.05). Meanwhile, RT-CES showed that the viability of malignant melanoma cells increased greatly in the presence of VEGF. When VEGF was 20 ng/ml, viability of the malignant melanoma cells increased by 40% compared with the negative control. There was no evident effect on proliferation of ARPE-19 (p>0.05). Furthermore, the growth of malignant melanoma cells was obviously inhibited after ranibizumab intervention. When ranibizumab was administered at 0.25 mg/ml, the survival rate of the malignant melanoma cells decreased to 57.5%. Nevertheless, low-dose exposure to ranibizumab had only a slight effect on the growth of ARPE-19, and PCR result demonstrated that VEGFR1 plays a role in this tumor tissue rather than VEGFR2.Ranibizumab can selectively inhibit malignant melanoma cell proliferation by decreasing the expression of VEGF; the possible mechanism of the inhibitory effect may involve VEGFR1 antagonism." @default.
• W74851999 created "2016-06-24" @default.
• W74851999 creator A5005686890 @default.
• W74851999 creator A5010599780 @default.
• W74851999 creator A5017541508 @default.
• W74851999 creator A5032452900 @default.
• W74851999 creator A5036202229 @default.
• W74851999 creator A5037826924 @default.
• W74851999 creator A5048780192 @default.
• W74851999 creator A5063922467 @default.
• W74851999 creator A5065243448 @default.
• W74851999 creator A5069122819 @default.
• W74851999 date "2014-01-01" @default.
• W74851999 modified "2023-09-26" @default.
• W74851999 title "The proliferation of malignant melanoma cells could be inhibited by ranibizumab via antagonizing VEGF through VEGFR1." @default.
• W74851999 cites W1506855898 @default.
• W74851999 cites W1875554126 @default.
• W74851999 cites W1971565191 @default.
• W74851999 cites W1972242350 @default.
• W74851999 cites W1991305397 @default.
• W74851999 cites W2000292756 @default.
• W74851999 cites W2007105443 @default.
• W74851999 cites W2012852444 @default.
• W74851999 cites W2013145271 @default.
• W74851999 cites W2013183971 @default.
• W74851999 cites W2019061366 @default.
• W74851999 cites W2020257494 @default.
• W74851999 cites W2025111444 @default.
• W74851999 cites W2029193079 @default.
• W74851999 cites W2030636749 @default.
• W74851999 cites W2037834317 @default.
• W74851999 cites W2046507292 @default.
• W74851999 cites W2061396971 @default.
• W74851999 cites W2063760352 @default.
• W74851999 cites W2065240552 @default.
• W74851999 cites W2073464835 @default.
• W74851999 cites W2086712008 @default.
• W74851999 cites W2101247829 @default.
• W74851999 cites W2109701118 @default.
• W74851999 cites W2111474798 @default.
• W74851999 cites W2112642558 @default.
• W74851999 cites W2121409064 @default.
• W74851999 cites W2125447919 @default.
• W74851999 cites W2144660856 @default.
• W74851999 cites W2145835533 @default.
• W74851999 cites W2147577701 @default.
• W74851999 cites W2157769714 @default.
• W74851999 cites W2160706109 @default.
• W74851999 cites W2161279821 @default.
• W74851999 cites W2169125392 @default.
• W74851999 cites W2363576709 @default.
• W74851999 cites W32167704 @default.
• W74851999 cites W47572136 @default.
• W74851999 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4021672" @default.
• W74851999 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24868139" @default.
• W74851999 hasPublicationYear "2014" @default.
• W74851999 type Work @default.
• W74851999 sameAs 74851999 @default.
• W74851999 citedByCount "6" @default.
• W74851999 countsByYear W748519992014 @default.
• W74851999 countsByYear W748519992018 @default.
• W74851999 countsByYear W748519992019 @default.
• W74851999 countsByYear W748519992020 @default.
• W74851999 countsByYear W748519992022 @default.
• W74851999 crossrefType "journal-article" @default.
• W74851999 hasAuthorship W74851999A5005686890 @default.
• W74851999 hasAuthorship W74851999A5010599780 @default.
• W74851999 hasAuthorship W74851999A5017541508 @default.
• W74851999 hasAuthorship W74851999A5032452900 @default.
• W74851999 hasAuthorship W74851999A5036202229 @default.
• W74851999 hasAuthorship W74851999A5037826924 @default.
• W74851999 hasAuthorship W74851999A5048780192 @default.
• W74851999 hasAuthorship W74851999A5063922467 @default.
• W74851999 hasAuthorship W74851999A5065243448 @default.
• W74851999 hasAuthorship W74851999A5069122819 @default.
• W74851999 hasConcept C126322002 @default.
• W74851999 hasConcept C142724271 @default.
• W74851999 hasConcept C167734588 @default.
• W74851999 hasConcept C202751555 @default.
• W74851999 hasConcept C203014093 @default.
• W74851999 hasConcept C2776694085 @default.
• W74851999 hasConcept C2777025900 @default.
• W74851999 hasConcept C2777658100 @default.
• W74851999 hasConcept C2777802072 @default.
• W74851999 hasConcept C2780394083 @default.
• W74851999 hasConcept C2781100027 @default.
• W74851999 hasConcept C502942594 @default.
• W74851999 hasConcept C54355233 @default.
• W74851999 hasConcept C55493867 @default.
• W74851999 hasConcept C62112901 @default.
• W74851999 hasConcept C71924100 @default.
• W74851999 hasConcept C81885089 @default.
• W74851999 hasConcept C86803240 @default.
• W74851999 hasConcept C95444343 @default.
• W74851999 hasConceptScore W74851999C126322002 @default.
• W74851999 hasConceptScore W74851999C142724271 @default.
• W74851999 hasConceptScore W74851999C167734588 @default.
• W74851999 hasConceptScore W74851999C202751555 @default.
• W74851999 hasConceptScore W74851999C203014093 @default.
• W74851999 hasConceptScore W74851999C2776694085 @default.

• next